SCHEMBL1663899

SCHEMBL1663899

COc1cccc(-n2c(C(C)C)nc3cc(O)ccc3c2=O)c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.54
ESR1 P03372 2/20 0.50
ESR2 Q92731 1/20 0.50
USP2 O75604 1/20 0.49
TP53 P04637 2/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
GAA P10253 2/20 0.47
PSMD14 O00487 1/20 0.47
POLB P06746 2/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
THRB P10828 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 1/20 0.44
RAB9A P51151 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663409 0.88 TRPV1 (0.69) TRPV1ESR1ESR2MEN1KMT2A
SCHEMBL10446410 0.80 TRPV1 (0.67) TRPV1SMN1; SMN2ESR1ESR2TP53
SCHEMBL1664439 0.79 TRPV1 (0.74) TRPV1SMN1; SMN2ESR1ESR2GAA
SCHEMBL1665294 0.79 TRPV1 (0.70) TRPV1SMN1; SMN2ESR1ESR2MEN1
SCHEMBL1664223 0.79 TRPV1 (0.55) TRPV1ESR1ESR2TP53MEN1
SCHEMBL1663637 0.78 TRPV1 (0.65) TRPV1SMN1; SMN2ESR1ESR2MEN1
SCHEMBL10446158 0.78 TRPV1 (0.72) TRPV1ESR1ESR2POLBMAPT
SCHEMBL1663398 0.78 TRPV1 (0.72) TRPV1SMN1; SMN2ESR1ESR2MEN1
SCHEMBL1664011 0.78 TRPV1 (0.72) TRPV1SMN1; SMN2ESR1ESR2MEN1
SCHEMBL1663746 0.78 TRPV1 (0.65) TRPV1ESR1ESR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885SMN1; SMN2 4016/4885ESR1 1321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.